Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CANCER THERAPY

The expanding universe of checkpoint inhibitors for nasopharyngeal cancer

Three phase 3 studies show that an immune-checkpoint inhibitor combined with chemotherapy improves progression-free survival in recurrent or metastatic nasopharyngeal cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Clinical development of immune-checkpoint inhibitors in recurrent or metastatic nasopharyngeal cancer.

References

  1. 1.

    Mai, H.Q. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01444-0 (2021).

  2. 2.

    Yang, Y. et al. Lancet Oncol. https://doi.org/10.1016/S1470-2045(21)00302-8 (2021)

  3. 3.

    BeiGene. https://ir.beigene.com/news-details/?id=29e026ba-7774-40a1-81f6-41d2321f1845 (21 May 2021).

  4. 4.

    Wong, K.C.W. et al. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-021-00524-x (2021).

  5. 5.

    GLOBOCAN. World Health Organization https://gco.iarc.fr/today/data/factsheets/cancers/4-Nasopharynx-fact-sheet.pdf 2020:

  6. 6.

    Wang, F. H. et al. J. Clin. Oncol. 39, 704–712 (2021).

    Article  Google Scholar 

  7. 7.

    Zhang, L. et al. Lancet 388, 1883–1892 (2016).

    CAS  Article  Google Scholar 

  8. 8.

    Sun, L. T. et al. Sci. Rep. 10, 2083 (2020).

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Gandhi, L. et al. N. Engl. J. Med. 378, 2078–2092 (2018).

    CAS  Article  Google Scholar 

  10. 10.

    Paz-Ares, L. et al. N. Engl. J. Med. 379, 2040–2051 (2018).

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Le, Q. T. et al. J. Natl. Cancer Inst. 111, 655–663 (2019).

    Article  PubMed  Google Scholar 

  12. 12.

    Yu, J. X. et al. Nat. Rev. Drug Discov. 19, 163–164 (2020).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Anthony T. C. Chan.

Ethics declarations

Competing interests

B.B.Y.M. is an advisory board member and receives speaker’s honoraria from Bristol Myers Squibb, Merck Serono, Merck Sharpe & Dohme (MSD) and Novartis, and is a consultant for Y-Biologics and Viracta Therapeutics. E.P.H. has received speaker’s honoraria from Merck Serono and MSD, and is a consultant and advisory board member for MSD. A.T.C.C. receives research funding from Merck Serono, MSD and Pfizer, and is an advisory board member for MSD and Tessa Therapeutics.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ma, B.B.Y., Hui, E.P. & Chan, A.T.C. The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. Nat Med 27, 1512–1513 (2021). https://doi.org/10.1038/s41591-021-01482-8

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing